The Different Ways Multi-Strain Probiotics with Different Ratios of <i>Bifidobacterium</i> and <i>Lactobacillus</i> Relieve Constipation Induced by Loperamide in MiceOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether multi-strain probiotic combinations of Bifidobacterium and Lactobacillus, mixed in four different ratios, could relieve constipation. Researchers built a mouse model of constipation using loperamide hydrochloride and then administered the probiotic blends for four weeks. They assessed changes in intestinal flora composition, short-chain fatty acid (SCFA) levels, gut motility-related hormones, and inflammatory markers. The goal was to compare how differently formulated probiotic blends might work through distinct mechanisms to relieve constipation.
Who was studied?
The subjects were mice with loperamide hydrochloride-induced constipation, used as an experimental model rather than human patients. Four different multi-strain probiotic formulations, varying in their ratio of Bifidobacterium to Lactobacillus, were tested in this model. The abstract does not give a specific number of animals per group or additional demographic detail, so no further population specifics can be stated.
What were the most important findings?
After four weeks, three formulations, BM1, BM2, and PB2, effectively relieved constipation, though through different pathways. The Bifidobacteria-dominated formulas BM1 and BM2 altered the composition and structure of the intestinal flora, decreasing Tyzzerella, Enterorhabdus, Faecalibaculum, Gordonibacter, and Mucispirillum while increasing Parabacteroides and stool SCFA content. These formulas also restored motilin (MTL) and vasoactive intestinal peptide (VIP) levels and downregulated serum IL-6 and IL-8, repairing the inflammatory response caused by constipation and promoting gastrointestinal peristalsis.
What are the greatest implications of this study?
The findings suggest that the ratio of Bifidobacterium to Lactobacillus in a multi-strain probiotic blend meaningfully changes its mechanism of action against constipation, not just its effectiveness. Bifidobacteria-dominated formulations appear to work by reshaping the gut microbiota, raising SCFA production, and correcting motility hormone and inflammatory imbalances. This points to the potential for tailoring probiotic strain ratios to target specific physiological pathways involved in constipation relief.